These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32711788)

  • 1. Dupilumab for nasal polyposis - Authors' reply.
    Bachert C; Mannent LP
    Lancet; 2020 Jul; 396(10246):233-234. PubMed ID: 32711788
    [No Abstract]   [Full Text] [Related]  

  • 2. Dupilumab for nasal polyposis.
    Lipworth B; Chan R; Kuo CR
    Lancet; 2020 Jul; 396(10246):233. PubMed ID: 32711789
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab Approved to Treat Chronic Rhinosinusitis with Nasal Polyposis.
    Aschenbrenner DS
    Am J Nurs; 2019 Oct; 119(10):21-22. PubMed ID: 31567245
    [No Abstract]   [Full Text] [Related]  

  • 5. Dupilumab in the treatment of nasal polyposis: A retrospective, real-world study.
    Nowsheen S; Darveaux JI
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):386-387. PubMed ID: 34022386
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
    Bachert C; Mannent L; Naclerio RM; Mullol J; Ferguson BJ; Gevaert P; Hellings P; Jiao L; Wang L; Evans RR; Pirozzi G; Graham NM; Swanson B; Hamilton JD; Radin A; Gandhi NA; Stahl N; Yancopoulos GD; Sutherland ER
    JAMA; 2016 Feb; 315(5):469-79. PubMed ID: 26836729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
    Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
    Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps.
    Bachert C; Gevaert P; Hellings P
    J Allergy Clin Immunol Pract; 2017; 5(6):1512-1516. PubMed ID: 28526278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nasal polyps and substance P: a preliminary report].
    Beatrice F; Aluffi P; Bottomicca F; Perlasco L; Sartoris A
    Acta Otorhinolaryngol Ital; 1994; 14 Suppl 41():35-9. PubMed ID: 7519816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory epithelial adenomatoid hamartoma with nasal polyps affects dupilumab efficacy.
    Takeda T; Yanagi N; Fukasawa N; Mori E; Maeda M; Sakaguchi R; Tei M; Omura K; Otori N
    Rhinology; 2022 Apr; 60(2):148-151. PubMed ID: 35174813
    [No Abstract]   [Full Text] [Related]  

  • 11. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.
    Bachert C; Zhang L; Gevaert P
    J Allergy Clin Immunol; 2015 Dec; 136(6):1431-1440. PubMed ID: 26654192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab: First Global Approval.
    Shirley M
    Drugs; 2017 Jul; 77(10):1115-1121. PubMed ID: 28547386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recalcitrant nasal polyposis: achievement of total remission following treatment with omalizumab.
    Guglielmo M; Gulotta C; Mancini F; Sacchi M; Tarantini F
    J Investig Allergol Clin Immunol; 2009; 19(2):158-9. PubMed ID: 19476021
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous Dupilumab and Mometasone Furoate Nasal Spray for Chronic Rhinosinusitis With Polyps.
    Schneider JS
    JAMA Otolaryngol Head Neck Surg; 2016 Jul; 142(7):698-9. PubMed ID: 27258602
    [No Abstract]   [Full Text] [Related]  

  • 15. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
    Gevaert P; Van Bruaene N; Cattaert T; Van Steen K; Van Zele T; Acke F; De Ruyck N; Blomme K; Sousa AR; Marshall RP; Bachert C
    J Allergy Clin Immunol; 2011 Nov; 128(5):989-95.e1-8. PubMed ID: 21958585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State of the art treatment of nasal polyposis.
    Aouad RK; Chiu AG
    Am J Rhinol Allergy; 2011; 25(5):291-8. PubMed ID: 22186240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress of monoclonal antibody treatment for chronic rhinosinusitis with or without nasal polyps].
    Chen YJ; Chai XB
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 May; 32(10):789-793. PubMed ID: 29873221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply: To PMID 23021878.
    Calus L; Hellings P; Brusselle G; Bachert C; Gevaert P
    J Allergy Clin Immunol; 2013 Jul; 132(1):247-8. PubMed ID: 23684071
    [No Abstract]   [Full Text] [Related]  

  • 19. Authors' Reply: Sinonasal polyposis recurrence rate and quality of life in the elderly.
    Brescia G; Barion U; Marioni G
    Am J Rhinol Allergy; 2017 Jan; 31(1):2. PubMed ID: 28234139
    [No Abstract]   [Full Text] [Related]  

  • 20. Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps.
    Kartush AG; Schumacher JK; Shah R; Patadia MO
    Am J Rhinol Allergy; 2019 Mar; 33(2):203-211. PubMed ID: 30587005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.